Altered Expression of HER-2 and the Mismatch Repair Genes MLH1 and MSH2 Predicts the Outcome of T1 High-grade Bladder Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2018 Jan 25

PMID 29362915

Citations 16

Authors

Francesca Sanguedolce

Antonella Cormio

Paolo Massenio

Maria C Pedicillo

Simona Cagiano

Francesca Fortunato

Beppe Calo

Giuseppe Di Fino

Giuseppe Carrieri

Pantaleo Bufo

Luigi Cormio

Affiliations

Soon will be listed here.

Abstract

Purpose: The identification of factors predicting the outcome of stage T1 high-grade bladder cancer (BC) is a major clinical issue.

Methods: We performed immunohistochemistry to assess the role of human epidermal growth factor receptor-2 (HER-2) and microsatellite instability (MSI) factors MutL homologue 1 (MLH1) and MutS homologue 2 (MSH2) in predicting recurrence and progression of T1 high-grade BCs having undergone transurethral resection of bladder tumor (TURBT) alone or TURBT + intravesical instillations of bacillus Calmette-Guerin (BCG).

Results: HER-2 overexpression was a significant predictor of disease-free survival (DFS) in the overall as well as in the two patients' population; as for progression-free survival (PFS), it was significant in the overall but not in the two patients' population. MLH1 was an independent predictor of PFS only in patients treated with BCG and MSH2 failed to predict DFS and PFS in all populations. Most importantly, the higher the number of altered markers the lowers the DFS and PFS. In multivariate Cox proportional-hazards regression analysis, the number of altered molecular markers and BCG treatment were significant predictors (p = 0.0004 and 0.0283, respectively) of DFS, whereas the number of altered molecular markers was the only significant predictor (p = 0.0054) of PFS.

Conclusions: Altered expression of the proto-oncogene HER-2 and the two molecular markers of genetic instability MLH1 and MSH2 predicted T1 high-grade BC outcome with the higher the number of altered markers the lower the DFS and PFS. These findings provide grounds for further testing them in predicting the outcome of this challenging disease.

Citing Articles

Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.

Soltani-Tehrani A, Kumar A, Pohar K Transl Cancer Res. 2024; 13(11):6489-6502.

PMID: 39697728 PMC: 11651738. DOI: 10.21037/tcr-24-180.

Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis.

Chandran E, Iannantuono G, Atiq S, Akbulut D, Sinaii N, Simon N BMJ Oncol. 2024; 3(1).

PMID: 39086924 PMC: 11203074. DOI: 10.1136/bmjonc-2024-000335.

Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.

Sanguedolce F, Falagario U, Zanelli M, Palicelli A, Zizzo M, Busetto G J Clin Med. 2024; 13(8).

PMID: 38673455 PMC: 11050441. DOI: 10.3390/jcm13082182.

An Evaluation of Fluorouracil plus Paclitaxel and Oxiliplatin as a First-Line Treatment for Advanced Gastric Squamous Cell Carcinoma.

Qin J, Shi Y, Zheng X, Lan Y, Zhang M, Liu M Evid Based Complement Alternat Med. 2023; 2023:2176371.

PMID: 37064950 PMC: 10101748. DOI: 10.1155/2023/2176371.

Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?.

Busetto G, Finati M, Chirico M, Cinelli F, dAltilia N, Falagario U World J Urol. 2023; 41(5):1329-1335.

PMID: 36971825 PMC: 10188396. DOI: 10.1007/s00345-023-04372-5.

References

Chen P, Yu H, Chang Y, Pan C . Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol. 2012; 66(2):113-9. DOI: 10.1136/jclinpath-2012-200944. View

Olsson H, Fyhr I, Hultman P, Jahnson S . HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. Scand J Urol Nephrol. 2011; 46(2):102-7. DOI: 10.3109/00365599.2011.637955. View

Cormio L, Tolve I, Annese P, Saracino A, Zamparese R, Sanguedolce F . Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res. 2009; 29(10):4201-4. View

Vaish M, Mandhani A, Mittal R, Mittal B . Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. BMC Urol. 2005; 5:2. PMC: 545959. DOI: 10.1186/1471-2490-5-2. View

Sanguedolce F, Cormio A, Bufo P, Carrieri G, Cormio L . Molecular markers in bladder cancer: Novel research frontiers. Crit Rev Clin Lab Sci. 2015; 52(5):242-55. DOI: 10.3109/10408363.2015.1033610. View

Bongiovanni L, Arena V, Vecchio F, Racioppi M, Bassi P, Pierconti F . HER-2 immunohistochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3). Arch Ital Urol Androl. 2013; 85(2):73-7. DOI: 10.4081/aiua.2013.2.73. View

Palou J, Sylvester R, Faba O, Parada R, Pena J, Algaba F . Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol. 2011; 62(1):118-25. DOI: 10.1016/j.eururo.2011.10.029. View

Czerniak B, Dinney C, McConkey D . Origins of Bladder Cancer. Annu Rev Pathol. 2016; 11:149-74. DOI: 10.1146/annurev-pathol-012513-104703. View

Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A . Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol. 2009; 21(4):815-819. PMC: 2844947. DOI: 10.1093/annonc/mdp488. View

10.

Cormio A, Sanguedolce F, Musicco C, Pesce V, Calo G, Bufo P . Mitochondrial dysfunctions in bladder cancer: Exploring their role as disease markers and potential therapeutic targets. Crit Rev Oncol Hematol. 2017; 117:67-72. DOI: 10.1016/j.critrevonc.2017.07.001. View

11.

Peltomaki P . DNA mismatch repair and cancer. Mutat Res. 2001; 488(1):77-85. DOI: 10.1016/s1383-5742(00)00058-2. View

12.

OBrien V, Brown R . Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis. 2005; 27(4):682-92. DOI: 10.1093/carcin/bgi298. View

13.

Saetta A, Goudopoulou A, Korkolopoulou P, Voutsinas G, Thomas-Tsagli E, Michalopoulos N . Mononucleotide markers of microsatellite instability in carcinomas of the urinary bladder. Eur J Surg Oncol. 2004; 30(7):796-803. DOI: 10.1016/j.ejso.2004.04.015. View

14.

Babjuk M, Bohle A, Burger M, Capoun O, Cohen D, Comperat E . EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2016; 71(3):447-461. DOI: 10.1016/j.eururo.2016.05.041. View

15.

Ding W, Tong S, Gou Y, Sun C, Wang H, Chen Z . Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol. 2015; 33(12):1951-7. DOI: 10.1007/s00345-015-1557-9. View

16.

Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J . Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 1997; 57(21):4749-56. View

17.

Jin T, Furihata M, Yamasaki I, Kamada M, Liang S, Ohtsuki Y . Human mismatch repair gene (hMSH2) product expression in relation to recurrence of transitional cell carcinoma of the urinary bladder. Cancer. 1999; 85(2):478-84. View

18.

Lammers R, Witjes J . Discussion on the influence of HER2 status on the clinical outcome of bladder cancer continues. Expert Rev Anticancer Ther. 2011; 11(6):853-8. DOI: 10.1586/era.11.58. View

19.

Moch H, Cubilla A, Humphrey P, Reuter V, Ulbright T . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016; 70(1):93-105. DOI: 10.1016/j.eururo.2016.02.029. View

20.

Loeb K, Loeb L . Significance of multiple mutations in cancer. Carcinogenesis. 2000; 21(3):379-85. DOI: 10.1093/carcin/21.3.379. View